0.8739

4.66% -0.0421

Jaguar Health Inc (JAGX)

Overview News Price History Financials Why JAGX Down? Discussions Forecast Stock Split

Jaguar Health Inc stock is traded at $0.8739, with a volume of 105.55K. It is down -4.66% in the last 24 hours and down -32.82% over the past month. Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Previous Close:

$0.916

Open:

$0.9

24h Volume:

105.55K

Relative Volume:

0.94

Market Cap:

$4.29M

Revenue:

$29.57M

Net Income/Loss:

$-34.68M

P/E Ratio:

-0.00123

EPS:

-708.7214

Net Cash Flow:

$-7.58M

1W Performance:

+4.66%

1M Performance:

-32.82%

6M Performance:

-95.55%

1Y Performance:

-98.69%

1-Day Range:

$0.86

$0.918

1-Week Range:

$0.725

$1.00

52-Week Range:

$0.725

$77.63

Jaguar Health Inc Stock (JAGX) Company Profile

Name

Jaguar Health Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

415-371-8300

Address

200 PINE STREET SUITE 400, SAN FRANCISCO, CA

Employee

Twitter

@Jaguar_Health

Next Earnings Date

2026-08-13

Latest SEC Filings

JAGX's Discussions on Twitter

Compare JAGX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
JAGX Jaguar Health Inc	0.8739	4.50M	29.57M	-34.68M	-7.58M	-708.72
VRTX Vertex Pharmaceuticals Inc	515.31	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.34	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.59	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.54	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.30	39.31B	5.76B	514.49M	1.10B	4.4813

Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-07-21	Initiated	Cantor Fitzgerald	Overweight
Jul-11-17	Initiated	Rodman & Renshaw	Buy

Jaguar Health Inc Stock (JAGX) Latest News

06:07 AM

Jaguar Health, Inc. SEC Filing (Aug 17, 2026) - Stock Titan

06:07 AM

Aug 14, 2026

Jaguar Health Delays Quarterly SEC Filing - TipRanks

Aug 14, 2026

Jaguar Health (JAGX) cites major subsequent events in delaying Q2 2026 10-Q - Stock Titan

Aug 14, 2026

Aug 11, 2026

Jaguar Health (JAGX) details 40.9M-share resale tied to $40M equity line - Stock Titan

Aug 11, 2026

Aug 05, 2026

Jaguar Health (JAGX) Secures $2 Million Holdback Payment from Fu - GuruFocus

Aug 05, 2026

Why is Jaguar Health stock gaining today? - Investing.com

Aug 05, 2026

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1 - ACCESS Newswire

Aug 05, 2026

After 12 Months, Crofelemer Cut Support Up to 48% in One MVID Patient - Stock Titan

Aug 05, 2026

Why is Jaguar Health stock gaining today? By Investing.com - Investing.com Australia

Aug 05, 2026

Aug 04, 2026

Jaguar Health (JAGX) Consolidates at $1.0: Support and Resistance Define Trading RangeMcClellan Summation - dars.gov.et

Aug 04, 2026

Jul 28, 2026

Jaguar Health (JAGX) Highlights Market Potential of Neonorm Dog Amidst Challenging Valuation - GuruFocus

Jul 28, 2026

Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog - Yahoo! Finance Canada

Jul 28, 2026

Almost 80% of Vet Oncologists Would Recommend Neonorm Dog - Stock Titan

Jul 28, 2026

Jul 27, 2026